

DAFTAR PUSTAKA

1. Damanhoury ZA. A Review on Therapeutic Potential of *Piper nigrum* L. (Black Pepper): The King of Spices. *Med Aromat Plants*. 2014;03(03).
2. Gorgani L, Mohammadi M, Najafpour GD, Nikzad M. Piperine—The Bioactive Compound of Black Pepper: From Isolation to Medicinal Formulations. *Compr Rev Food Sci Food Saf*. 2017;16(1):124–40.
3. Haq IU, Imran M, Nadeem M, Tufail T, Gondal TA, Mubarak MS. Piperine: A review of its biological effects. *Phyther Res*. 2021;35(2):680–700.
4. Tiwari A, Mahadik KR, Gabhe SY. Piperine: A comprehensive review of methods of isolation, purification, and biological properties. *Med Drug Discov* [Internet]. 2020;7:100027. Available from: <https://doi.org/10.1016/j.medidd.2020.100027>
5. Shattat GF. A review article on hyperlipidemia: Types, treatments and new drug targets. *Biomed Pharmacol J*. 2014;7(2):399–409.
6. Damdindorj M, Borjihan G, Gendaram O, Bold B. Synthesis and antihyperlipidaemic activity of a new piperine derivative. *Mong J Chem*. 2021;22(48):13–8.
7. Shah SS, Shah GB, Singh SD, Gohil P V., Chauhan K, Shah KA, et al. Effect of piperine in the regulation of obesity-induced dyslipidemia in high-fat diet rats. *Indian J Pharmacol*. 2011;43(3):296–9.
8. Maneesai P, Scholfield CN, Chootip K. Piperine is Anti-hyperlipidemic and Improves Endothelium-dependent Vasorelaxation in Rats on a High Cholesterol Diet. *J Physiol Biomed Sci*. 2012;25(1):27–30.
9. Tunsophon S, Chootip K. Comparative effects of piperine and simvastatin in fat accumulation and antioxidative status in high fat-induced hyperlipidemic rats. *Can J Physiol Pharmacol* [Internet]. 2016 Dec;94(12):1344–8. Available from: <http://www.nrcresearchpress.com/doi/10.1139/cjpp-2016-0193>
10. Zaini E, Riska D, Oktavia MD, Ismed F, Fitriani L. Improving Dissolution Rate of Piperine by Multicomponent Crystal Formation with Saccharin. *Res*

- J Pharm Technol [Internet]. 2020;13(4):1928. Available from: <http://www.indianjournals.com/ijor.aspx?target=ijor:rjpt&volume=13&issue=4&article=057>
11. Salsabila H, Fitriani L, Zaini E. Recent strategies for improving solubility and oral bioavailability of piperine. *Int J Appl Pharm*. 2021;13(4):31–9.
 12. Zaini E, Afriyani, Fitriani L, Ismed F, Horikawa A, Uekusa H. Improved solubility and dissolution rates in novel multicomponent crystals of piperine with succinic acid. *Sci Pharm*. 2020;88(2).
 13. Sari YN, Zaini E, Ismed F. Peningkatan Laju Disolusi Piperine dengan Pembentukan Multikomponen Kristal Menggunakan Asam Nikotinat. *J Sains Farm Klin* [Internet]. 2019 Aug 28;6(2):180–5. Available from: <http://jsfk.ffarmasi.unand.ac.id/index.php/jsfk/article/view/439>
 14. Stasiłowicz A, Rosiak N, Tykarska E, Kozak M, Jenczyk J, Szulc P, et al. Combinations of piperine with hydroxypropyl- β -cyclodextrin as a multifunctional system. *Int J Mol Sci*. 2021;22(8).
 15. Thenmozhi K, Yoo YJ. Enhanced solubility of piperine using hydrophilic carrier-based potent solid dispersion systems. *Drug Dev Ind Pharm* [Internet]. 2017;43(9):1501–9. Available from: <http://dx.doi.org/10.1080/03639045.2017.1321658>
 16. Bhalekar MR, Madgulkar AR, Desale PS, Marium G. Formulation of piperine solid lipid nanoparticles (SLN) for treatment of rheumatoid arthritis. *Drug Dev Ind Pharm* [Internet]. 2017;43(6):1003–10. Available from: <http://dx.doi.org/10.1080/03639045.2017.1291666>
 17. Fitriani L, Fitriandi AD, Hasanah U, Zaini E. Nano-Cocrystals of Piperine-Succinic Acid: Physicochemical Characterization and Dissolution Rate Studies. *ChemistrySelect* [Internet]. 2022 Apr 12;7(14). Available from: <https://onlinelibrary.wiley.com/doi/10.1002/slct.202104196>
 18. Stojanović-Radić Z, Pejčić M, Dimitrijević M, Aleksić A, Anil Kumar N V., Salehi B, et al. Piperine-A Major Principle of Black Pepper: A review of its bioactivity and studies. *Appl Sci*. 2019;9(20):1–29.
 19. Quijia CR, Araujo VH, Chorilli M. Piperine: Chemical, biological and nanotechnological applications. *Acta Pharm*. 2021;71(2):185–213.

20. Vasavirama K, Upender M. Piperine: A valuable alkaloid from piper species. *Int J Pharm Pharm Sci.* 2014;6(4):34–8.
21. Smilkov K, Ackova DG, Cvetkovski A, Ruskovska T, Vidovic B, Atalay M. Piperine: Old Spice and New Nutraceutical? *Curr Pharm Des.* 2019;25(15):1729–39.
22. Meghwal M, Goswami TK. *Piper nigrum* and piperine: An update. *Phyther Res.* 2013;27(8):1121–30.
23. Quijia CR, Chorilli M. Characteristics, Biological Properties and Analytical Methods of Piperine: A Review. *Crit Rev Anal Chem* [Internet]. 2020;50(1):62–77. Available from: <https://doi.org/10.1080/10408347.2019.1573656>
24. Nghiem NP, Kleff S, Schwegmann S. Succinic acid: Technology development and commercialization. *Fermentation.* 2017;3(2):1–14.
25. Jiang X, Hu Y, Meng Z, Yang W, Shen F. Solubility of succinic acid in different aqueous solvent mixtures: Experimental measurement and thermodynamic modeling. *Fluid Phase Equilib* [Internet]. 2013;341(30):7–11. Available from: <http://dx.doi.org/10.1016/j.fluid.2012.12.018>
26. Johan, Wouters QL. *Pharmaceutical Salts and Co-crystals* [Internet]. Pharmaceutical salts and co-crystals. 2011. 406 p. Available from: <http://ebook.rsc.org/?DOI=10.1039/9781849733502>
27. Hu YH, Chen ZG, Yang WG, Shi Y, Sun HL, Li YL. Solubility of succinic acid in ethanol plus water systems from 278.15 K to 333.15 K. *J Solution Chem.* 2013;42(1):102–10.
28. Chiang CJ, Hu RC, Huang ZC, Chao YP. Production of Succinic Acid from Amino Acids in *Escherichia coli*. *J Agric Food Chem.* 2021;69(29):8172–8.
29. Wang H, Xia B, Lin M, Wang Y, Sun B, Li Y. Succinic acid inhibits the activity of cytochrome P450 (CYP450) enzymes. *Pharm Biol* [Internet]. 2020 Jan 1;58(1):1159–64. Available from: <https://doi.org/10.1080/13880209.2020.1839110>
30. Cerreia Vioglio P, Chierotti MR, Gobetto R. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges. *Adv Drug Deliv Rev* [Internet]. 2017;117:86–110. Available from: <https://doi.org/10.1016>

/j.addr.2017.07.001

31. Almeida E Sousa L, Reutzel-Edens SM, Stephenson GA, Taylor LS. Supersaturation Potential of Salt, Co-Crystal, and Amorphous Forms of a Model Weak Base. *Cryst Growth Des.* 2016;16(2):737–48.
32. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharm* [Internet]. 2012 Jul 5;2012:1–10. Available from: <https://www.hindawi.com/journals/isrn/2012/195727/>
33. Putri D. Review: Multi-Component Crystals: Cinnamic Acid As A Co-Former. *Int J Pharm Sci Med.* 2021;6(1):92–8.
34. Grothe E, Meekes H, Vlieg E, Ter Horst JH, De Gelder R. Solvates, Salts, and Cocrystals: A Proposal for a Feasible Classification System. *Cryst Growth Des.* 2016;16(6):3237–43.
35. Clarke HD. Crystal Engineering of Multi-Component Crystal Forms: The Opportunities and Challenges in Design. *ProQuest Diss Theses.* 2012;(January):153.
36. Healy AM, Worku ZA, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. *Adv Drug Deliv Rev* [Internet]. 2017;117:25–46. Available from: <https://doi.org/10.1016/j.addr.2017.03.002>
37. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: An overview. *Int J Pharm* [Internet]. 2011;419(1–2):1–11. Available from: <http://dx.doi.org/10.1016/j.ijpharm.2011.07.037>
38. Permatasari D, Ramadhani S, Sopyan I. Ko-Kristal: Teknik Pembuatan Ko-Kristal. *Farmaka* [Internet]. 2016;14(4):98–115. Available from: <http://jurnal.unpad.ac.id/farmaka/article/view/10461/5073>
39. Patole T, Deshpande A. Co-Crystallization - A Technique For Solubility Enhancement. *Int J Pharm Sci Res.* 2014;5(9):3566–76.
40. Al-Kassas R, Bansal M, Shaw J. Nanosizing techniques for improving bioavailability of drugs. *J Control Release* [Internet]. 2017;260:202–12. Available from: <http://dx.doi.org/10.1016/j.jconrel.2017.06.003>
41. Shargel L, Yu AB. *Applied Biopharmaceutics and Pharmacokinetics.* Seventh Ed. McGraw-Hill Education; 2016. 1–910 p.

42. Chang TL, Zhan H, Liang D, Liang JF. Nanocrystal technology for drug formulation and delivery. *Front Chem Sci Eng*. 2015;9(1).
43. Liu M, Hong C, Li G, Ma P, Xie Y. The generation of myricetin-nicotinamide nanococrystals by top down and bottom up technologies. *Nanotechnology* [Internet]. 2016;27(39):1–8. Available from: <http://dx.doi.org/10.1088/0957-4484/27/39/395601>
44. Kulkarni SA, Myerson AS. *Engineering Crystallography: From Molecule to Crystal to Functional Form* [Internet]. Roberts KJ, Docherty R, Tamura R, editors. Dordrecht: Springer Netherlands; 2017. (NATO Science for Peace and Security Series A: Chemistry and Biology). Available from: <http://link.springer.com/10.1007/978-94-024-1117-1>
45. Joseph E, Singhvi G. Multifunctional nanocrystals for cancer therapy: a potential nanocarrier. In: *Nanomaterials for Drug Delivery and Therapy* [Internet]. Elsevier; 2019. p. 91–116. Available from: <http://dx.doi.org/10.1016/B978-0-12-816505-8.00007-2>
46. Akbari B, Tavandashti MP, Zandrahimi M. Particle Size Characterization of Nanoparticles- A Practical Approach. *Iran J Mater Sci Eng*. 2011;8(2):48–56.
47. Kumar A, Dixit CK. Methods for characterization of nanoparticles. In: *Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids* [Internet]. Elsevier; 2017. p. 43–58. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B9780081005576000031>
48. Mudalige T, Qu H, Van Haute D, Ansar SM, Paredes A, Ingle T. Characterization of Nanomaterials. In: *Nanomaterials for Food Applications* [Internet]. Elsevier; 2019. p. 313–53. Available from: <http://dx.doi.org/10.1016/B978-0-12-814130-4.00011-7>
49. Bunaciu AA, Udriștiouiu E gabriela, Aboul-Enein HY. X-Ray Diffraction: Instrumentation and Applications. *Crit Rev Anal Chem* [Internet]. 2015 Oct 2;45(4):289–99. Available from: <http://www.tandfonline.com/doi/full/10.1080/10408347.2014.949616>
50. Trinick TR, Duly EB. Hyperlipidemia: Overview. *Encycl Hum Nutr*. 2012;2–4:442–52.

51. Fahy E, Cotter D, Sud M, Subramaniam S. Lipid classification, structures and tools. *Biochim Biophys Acta - Mol Cell Biol Lipids*. 2011; 1811(11):637–47.
52. DiPiro JT, Wells BG, Schwinghammer TL, DiPiro C V. *Pharmacotherapy Handbook*. ninth edit. DiPiro JT, Wells BG, Schwinghammer TL, DiPiro C V, editors. Vol. 44. New York: Mc Graw Hill Education; 2015.
53. Verma N. Introduction To Hyperlipidemia and Its Treatment: a Review. *Int J Curr Pharm Res*. 2016;9(1):6.
54. Brunton LL, Hilal-Dandan R, Knollmann B. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 13th editi. Brunton LL, Hilal-Dandan R, Knollmann B, editors. *The Routledge Companion to Aesthetics*. New York: Mc Graw Hill Education; 2017. 605–618 p.
55. Baynes JW, Dominiczak MH. *Medical Biochemistry*, 4th edition. 4th editio. Saunders Elsevier; 2014. 1021–1111 p.
56. Freeman MW, Walford GA. Lipoprotein Metabolism and the Treatment of Lipid Disorders [Internet]. Seventh Ed. Vols. 1–2, *Endocrinology: Adult and Pediatric*. Elsevier Inc.; 2015. 715-736.e7 p. Available from: <http://dx.doi.org/10.1016/B978-0-323-18907-1.00041-X>
57. Lee CK, Liao CW, Meng SW, Wu WK, Chiang JY, Wu MS. Lipids and lipoproteins in health and disease: Focus on targeting atherosclerosis. *Biomedicines*. 2021;9(8):1–22.
58. Liu E, Fan J, editors. *Fundamental of Laboratory Animal Science*. CRC Press is an imprint of Taylor & Francis Group; 2018.
59. Hrapkiewicz K, Colby L, Denison P. *Clinical Laboratory Animal Medicine*. Fourth Edi. John Wiley & Sons, Inc. Third; 2013.
60. Mahdi C, Citrawati P, Hendrawan VF. The Effect of Rice Bran on Triglyceride Levels and Histopatologic Aorta in Rat (*Rattus norvegicus*) of High Cholesterol Dietary Model. *IOP Conf Ser Mater Sci Eng* [Internet]. 2020 May 1;833(1):012022. Available from: <https://iopscience.iop.org/article/10.1088/1757-899X/833/1/012022>
61. Riesanti DG, Padaga MC, Herawati. Kadar HDL, kadar LDL, dan Gambaran Histopatologi Aorta pada Hewan Model Tikus (*Rattus norvegicus*)

- Hiperkolesterolemia dengan Terapi Ekstrak Air Benalu Manga (*Dendrophthoe pentandra*). 2013;
62. Lin CF, Chang YH, Chien SC, Lin YH, Yeh HY. Epidemiology of Dyslipidemia in the Asia Pacific Region. *Int J Gerontol*. 2018;12(1):2–6.
 63. Nouh F, Omar M, Younis M. Risk Factors and Management of Hyperlipidemia (Review). *Asian J Cardiol Res* [Internet]. 2019;2(1):1–10. Available from: <http://www.sciencedomain.org/review-history/28002>
 64. Anggraini DI, Nabillah LF. Activity Test of Suji Leaf Extract (*Dracaena angustifolia* Roxb.) on in vitro cholesterol lowering. *J Kim Sains dan Apl*. 2018;21(2):54–8.
 65. Pradana MS, Suryanto I. Terapi Hiperkolesterol pada Mencit (*Mus musculus*) strain Balb/C Betina Umur 2 Bulan Menggunakan Sari Bawang Putih. *Biota* [Internet]. 2017 Aug 8;3(2):71. Available from: <http://jurnal.radenfatah.ac.id/index.php/biota/article/view/1313>
 66. Saikia M, Phukan JK, Gogoi B, Goswami RK. A Comparative Study of Serum Fasting Lipid Profile between Normotensive, Non-Diabetic Glaucoma Patients with Healthy Non-Glaucoma Individuals. *Int J Adv Res* [Internet]. 2016;4(4):565–9. Available from: <http://www.journalijar.com>
 67. Rohman A. Validasi dan Penjaminan Mutu Metode Analisis Kimia. Yogyakarta: Gajah Mada University Press; 2018. 238 p.
 68. Hock FJ. Drug Discovery and Evaluation: Pharmacological Assays [Internet]. Hock FJ, editor. Cham: Springer International Publishing; 2016. Available from: <http://link.springer.com/10.1007/978-3-319-05392-9>
 69. HARINI M, ASTIRIN OP. Blood cholesterol levels of hypercholesterolemic rat (*Rattus norvegicus*) after VCO treatment. *Nusant Biosci*. 2009;1(2):53–8.
 70. Sibarani J, Atik TTN, Rachmadi D, Mustafa A. Urinary cytochrome c and caspase-3 as novel biomarker of renal function impairment in unilateral ureteropelvic junction obstruction model of wistar rats. *Res Reports Urol*. 2020;12:217–24.
 71. Pubchem. Piperine [Internet]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/638024>

72. Pubchem. Succinic Acid [Internet]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/1110>
73. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Sixth Edit. Pharmaceutical Press; 2009.
74. Wigayati EM, Raden D, Purawardi I. Analisis Pengaruh Mechanical Milling Menggunakan Planetary Ball Terhadap Struktur Kristal dan Struktur Mikro Senyawa LiBOB. J Sains Mater Indones. 2015;16(3):126–32.
75. Taurina W, Sari R, Hafinur UC, Wahdaningsih S, Isnindar. Optimasi kecepatan dan lama pengadukan terhadap ukuran nanopartikel kitosan-ekstrak etanol 70% kulit jeruk siam (*Citrus nobilis* L.var Microcarpa). Tradit Med J. 2017;22(1):16–20.
76. Wang H, Yuan L, An J. Crystallographic Characteristics of Hydroxylapatite in Hard Tissues of Cololabis saira. Crystals [Internet]. 2017 Apr 5;7(4):103. Available from: <http://www.mdpi.com/2073-4352/7/4/103>
77. Murti YB, Hartini YS, Hinrichs WLJ, Frijlink HW, Setyaningsih D. UV-Vis Spectroscopy to Enable Determination of the Dissolution Behavior of Solid Dispersions Containing Curcumin and Piperine. J Young Pharm [Internet]. 2018 Jan 17;11(1):26–30. Available from: <http://www.jyoungpharm.org/article/1302>
78. Bao L, Bai S, Borijihan G. Hypolipidemic effects of a new piperine derivative GB-N from *Piper longum* in high-fat diet-fed rats. Pharm Biol. 2012;50(8):962–7.
79. Rahmi E, Dharsana P. Antihyperlipidemic activity and mechanism test of cashew nut shell extract in male wistar rat induced by high - cholesterol foods. Farmasains J Farm dan Ilmu Kesehat. 2021;6(1):1–7.
80. Siregar FA, Makmur T. Metabolisme Lipid Dalam Tubuh. J Inov Kesehat Masy [Internet]. 2020;1(2):60–5. Available from: <http://ejournal.delihusada.ac.id/index.php/JIKM>
81. Morgan AE, Mooney KM, Wilkinson SJ, Pickles NA, Mc Auley MT. Investigating cholesterol metabolism and ageing using a systems biology approach. Proc Nutr Soc [Internet]. 2017 Aug 2;76(3):378–91. Available from: <https://www.cambridge.org/core/product/identifier/S0029665116002>

822/type/journal_article

82. Aa A, Mustofa S, Susantiningsih T. The Effect of 95 % Ethanol Extract of Javanese Long Pepper (*Piper retrofractum Vahl.*) to Total Cholesterol and Triglyceride Levels in Male Sprague dawley Rats (*Rattus novergicus*) Administrated by High Fat Diet Ca. Issn 2337-3776. 2014;1–10.

